Ravit Geva

List of Publications by Year
in descending order

94 papers	8,168 citations	218662 26 h-index	82542 72 g-index
96 all docs	96 docs citations	96 times ranked	11221 citing authors

#	Article	IF	Citations
1	First-in-Class Anti-immunoglobulinâ€“like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 57-70.	7.0	30
2	Oncologic patientsâ€™ misconceptions may impede enrollment into clinical trials: a cross-sectional study. BMC Medical Research Methodology, 2022, 22, 5.	3.1	5
3	Open-label phase 1/2 study evaluating the tolerability and antitumor activity of selinexor and pembrolizumab in colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 110-110.	1.6	0
4	Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome. Current Medical Research and Opinion, 2022, 38, 579-586.	1.9	0
5	Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discovery, 2022, 12, 1248-1265.	9.4	36
6	Abstract CT129: A multicohort, open-label, phase 2 basket study of the coformulation of vibostolimab with pembrolizumab, with or without other anticancer therapies, in select solid tumors. Cancer Research, 2022, 82, CT129-CT129.	0.9	0
7	Phase 1 first-in-human trial of MTB-9655, the first oral inhibitor of ACSS2, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, e20609-e20609.	1.6	3
8	Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis. Clinical Research in Cardiology, 2021, 110, 50-60.	3.3	20
9	Effect of cannabis on oxaliplatin-induced peripheral neuropathy among oncology patients: a retrospective analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199020.	3.2	19
10	Rapid Implementation of Telemedicine During the COVID-19 Pandemic: Perspectives and Preferences of Patients with Cancer. Oncologist, 2021, 26, e679-e685.	3.7	75
11	Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer.. Journal of Clinical Oncology, 2021, 39, e15579-e15579.	1.6	1
12	Verification of statistical oncological endpoints on encrypted data: Confirming the feasibility of real-world data sharing without the need to reveal protected patient information.. Journal of Clinical Oncology, 2021, 39, e18725-e18725.	1.6	1
13	Comparing implementation of Telemedicine compliance and feasibility among oncology patients across countries during the COVID 19 pandemic.. Journal of Clinical Oncology, 2021, 39, e13622-e13622.	1.6	0
14	Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. Clinical Cancer Research, 2021, 27, 5020-5027.	7.0	37
15	Abstract CT177: A multi-center phase 2a trial of the CXCR4 inhibitor motixafortide (BL-8040) (M) in combination with pembrolizumab (P) and chemotherapy (C), in patients with metastatic pancreatic adenocarcinoma (mPDAC). Cancer Research, 2021, 81, CT177-CT177.	0.9	2
16	First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. , 2021, 9, e002863.		20
17	Lymph Node Metastases from Visceral Peritoneal Colorectal Metastases are Associated with Systemic Recurrence. Annals of Surgical Oncology, 2021, , 1.	1.5	3
18	Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study. Nutrients, 2021, 13, 4295.	4.1	11

#	Article	IF	Citations
19	ASO Visual Abstract: LymphÂNodeÂMetastasesÂfromÂVisceralÂPeritonealÂColorectal MetastasesÂare Associated with Systemic Recurrence. Annals of Surgical Oncology, 2021, , 1.	1.5	1
20	539â€…Phase 1 study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L/IL-23/IL-36Î³, for intratumoral (ITu) injection +/- durvalumab in advanced solid tumors and lymphoma. , 2021, 9, A569-A569.		14
21	Resection Versus Observation of Small Asymptomatic Nonfunctioning Pancreatic Neuroendocrine Tumors. Journal of Gastrointestinal Surgery, 2020, 24, 1366-1374.	1.7	26
22	Prognostic significance of pancreatic fistula and postoperative complications after pancreaticoduodenectomy in patients with pancreatic ductal adenocarcinoma. Journal of the Royal College of Surgeons of Edinburgh, 2020, 18, 24-30.	1.8	7
23	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repairâ€“Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology, 2020, 38, 1-10.	1.6	1,740
24	Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instabilityâ€“High/Mismatch Repairâ€“Deficient Metastatic Colorectal Cancer: KEYNOTE-164. Journal of Clinical Oncology, 2020, 38, 11-19.	1.6	623
25	Firstâ€inâ€human phase 1 study of MKâ€1248, an antiâ€“glucocorticoidâ€induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. Cancer, 2020, 126, 4926-4935.	4.1	46
26	Ramucirumab and durvalumab for previously treated, advanced nonâ€“small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). European Journal of Cancer, 2020, 137, 272-284.	2.8	86
27	Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. Investigational New Drugs, 2020, 38, 1411-1420.	2.6	14
28	Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 3963-3970.	1.5	55
29	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nature Medicine, 2020, 26, 878-885.	30.7	297
30	412â€…First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBodyÂ®-PD-L1Ã—4â€“1BB (GEN1046) in patients with advanced solid tumors. , 2020, , .		5
31	A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36Î³, for intratumoral (iTu) injection alone and in combination with durvalumab.. Journal of Clinical Oncology, 2020, 38, 3092-3092.	1.6	39
32	A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.. Journal of Clinical Oncology, 2020, 38, 3094-3094.	1.6	5
33	Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study.. Journal of Clinical Oncology, 2020, 38, 4032-4032.	1.6	10
34	A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT).. Journal of Clinical Oncology, 2020, 38, TPS4672-TPS4672.	1.6	29
35	A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2020, 38, TPS3160-TPS3160.	1.6	1
36	Resection vs Transplant Listing for Hepatocellular Carcinoma: An Intention-to-Treat Analysis. Transplantation Proceedings, 2019, 51, 1867-1873.	0.6	5

#	Article	IF	Citations
37	Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study. Future Oncology, 2019, 15, 2723-2731.	2.4	29
38	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer, 2019, 22, 828-837.	5.3	181
39	Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location. Oncologist, 2019, 24, e696-e701.	3.7	6
40	Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study. Supportive Care in Cancer, 2019, 27, 3027-3033.	2.2	8
41	Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1092-1101.	6.4	13
42	A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 2527-2527.	1.6	8
43	Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s).. Journal of Clinical Oncology, 2019, 37, 2528-2528.	1.6	23
44	Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.. Journal of Clinical Oncology, 2019, 37, 4009-4009.	1.6	14
45	An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.. Journal of Clinical Oncology, 2019, 37, 140-140.	1.6	37
46	Data from an integrated cancer prevention center screening for multiple cancer types.. Journal of Clinical Oncology, 2019, 37, e13069-e13069.	1.6	2
47	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. JAMA Oncology, 2018, 4, e180013.	7.1	1,350
48	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. British Journal of Cancer, 2018, 119, 153-159.	6.4	329
49	Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. European Journal of Surgical Oncology, 2018, 44, 1619-1623.	1.0	82
50	LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 871-879.	7.3	80
51	Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. Cancer Biology and Therapy, 2018, 19, 871-874.	3.4	18
52	First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, 3029-3029.	1.6	13
53	KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 3514-3514.	1.6	63
54	Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.. Journal of Clinical Oncology, 2018, 36, 88-88.	1.6	4

#	Article	IF	Citations
55	Current Status of mCRC in East Europe and Middle East.. Journal of Clinical Oncology, 2018, 36, 853-853.	1.6	0
56	Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.. Journal of Clinical Oncology, 2018, 36, 276-276.	1.6	1
57	Ten year mortality trends among Israeli pancreatic ductal adenocarcinoma (PDAC) patients.. Journal of Clinical Oncology, 2018, 36, e16222-e16222.	1.6	0
58	Life expectancy and early detection of neoplasia: One stop screening for multiple cancer typesâ€"11 year (2006-2017) experience of an integrated cancer prevention center (ICPC).. Journal of Clinical Oncology, 2018, 36, e13553-e13553.	1.6	0
59	Surgical Treatment of Hepatocellular Carcinoma with a Tumor Thrombus Extending into the Right Atrium. Israel Medical Association Journal, 2018, 20, 590-591.	0.1	2
60	Acupuncture and Reflexology for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer. Integrative Cancer Therapies, 2017, 16, 258-262.	2.0	29
61	Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.. Journal of Clinical Oncology, 2017, 35, 3071-3071.	1.6	107
62	KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.. Journal of Clinical Oncology, 2017, 35, 4012-4012.	1.6	55
63	Sidedness matters: Surrogate biomarkers prognosticate colorectal cancer upon anatomic location.. Journal of Clinical Oncology, 2017, 35, 523-523.	1.6	1
64	Ten year experience of an integrated cancer prevention center screening for multiple cancer types.. Journal of Clinical Oncology, 2017, 35, 1549-1549.	1.6	0
65	Oncologic patients attitudes and participation in clinical trials.. Journal of Clinical Oncology, 2017, 35, e18029-e18029.	1.6	0
66	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Journal of Clinical Oncology, 2016, 34, 2460-2467.	1.6	1,185
67	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncology, The, 2016, 17, 717-726.	10.7	943
68	Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients. Value in Health, 2016, 19, 82-87.	0.3	16
69	RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.. Journal of Clinical Oncology, 2016, 34, 4110-4110.	1.6	26
70	Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology, 2016, 34, 6010-6010.	1.6	25
71	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.. Journal of Clinical Oncology, 2016, 34, 6012-6012.	1.6	33
72	KEYNOTE-164: Phase 2 study of pembrolizumab for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma.. Journal of Clinical Oncology, 2016, 34, TPS3631-TPS3631.	1.6	4

#	Article	IF	Citations
73	Safety and activity of topical 4% doxycycline foam (FDX104) in epidermal growth factor receptor inhibitor (EGFRI) induced skin toxicity.. Journal of Clinical Oncology, 2016, 34, 10130-10130.	1.6	0
74	CD24 and APC Genetic Polymorphisms in Pancreatic Cancers as Potential Biomarkers for Clinical Outcome. PLoS ONE, 2015, 10, e0134469.	2.5	5
75	Predictive Levels of CD24 in Peripheral Blood Leukocytes for the Early Detection of Colorectal Adenomas and Adenocarcinomas. Disease Markers, 2015, 2015, 1-9.	1.3	10
76	Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. BioMed Research International, 2015, 2015, 1-9.	1.9	6
77	Randomized controlled trial of Inquiry-Based Stress Reduction (IBSR) technique forBRCA1/2mutation carriers. Psycho-Oncology, 2015, 24, 726-731.	2.3	9
78	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut, 2015, 64, 921-928.	12.1	22
79	â€œThe Role of Primary Tumor Resection (PTR) in Metastatic Colorectal Cancerâ€• Current Colorectal Cancer Reports, 2015, 11, 225-230.	0.5	0
80	Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475).. Journal of Clinical Oncology, 2015, 33, 3026-3026.	1.6	16
81	Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012.. Journal of Clinical Oncology, 2015, 33, 4001-4001.	1.6	28
82	Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012.. Journal of Clinical Oncology, 2015, 33, 3-3.	1.6	58
83	Is there a role for adjuvant chemotherapy in pathological complete response rectal cancer tumors following neoadjuvant chemoradiotherapy?. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1489-1494.	2.5	32
84	A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS3119-TPS3119.	1.6	0
85	Next-generation sequencing (NGS) in metastatic colorectal cancer (CRC) patients (pts) in Israel.. Journal of Clinical Oncology, 2014, 32, e14548-e14548.	1.6	0
86	A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation.. Journal of Clinical Oncology, 2014, 32, TPS4161-TPS4161.	1.6	2
87	The Optimal Staging of Rectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 24-30.	0.5	0
88	Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. OncoTargets and Therapy, 2013, 6, 53.	2.0	13
89	Molecular profiling (MP)-selected therapy for the treatment of patients with advanced pancreaticobiliary cancer (PBC).. Journal of Clinical Oncology, 2013, 31, 195-195.	1.6	0
90	APC I1307K polymorphism as a predictive factor for colorectal neoplasia recurrence.. Journal of Clinical Oncology, 2013, 31, 1526-1526.	1.6	0

#	Article	IF	Citations
91	Association of the colon cancer recurrence score with treatments received in patients with stage II colon cancer: The Clalit Health Services experience.. Journal of Clinical Oncology, 2013, 31, e22111-e22111.	1.6	0
92	The APC I1307K polymorphism as a significant risk factor for CRC in average-risk Ashkenazi Jews.. Journal of Clinical Oncology, 2012, 30, 1507-1507.	1.6	0
93	MYC gene copy number (GCN) and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2012, 30, e21018-e21018.	1.6	0
94	The Co-occurrence of Breast Cancer and Soft Tissue Sarcoma in a Single Cohort Series. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 34-37.	1.3	4